Main Content

“2020health is an important and thoughtful contributor to the health debate”

Dr Sarah Wollaston MP, Chairman, Health Select Committee


‘Personalised Medicines: Can There Ever be a Right of Access?’

Feb 10. till Feb 10.

Invitation Only Intelligence Exchange

Kindly hosted by Jeremy Lefroy MP

With guest speakers:
Zoë Molyneux, Senior Policy Adviser, Cancer Research UK
Dr Zahid Latif, Head of Health & Care, Innovate UK
Charlotte Phelps, General Manager, Nordic Pharma UK & EMIG Group Member

The event will consider the anticipated growth in the development of personalised medicines for patients and whether these could represent value for the NHS and the taxpayer at large. The NHS constitution currently promises us that we can have access to NICE approved medication, but already local decision making undermines this and the high initial cost of personalised treatment poses a real challenge. Additionally, the smaller the target group for a treatment is, the less likely it is that NICE will assess the drug so it won’t have a HTA ‘mandate’. Medical R&D, as you know, is crucial to our economy, so what are the prospects for innovation and uptake?

February 10, 20162016-02-10T04:00:00 - February 10, 2016 2016-02-10T05:30:06
4:00 PM 2016-02-10T04:00:00 - 5:30 PM 2016-02-10T05:30:06
Portcullis House, Westminster